# PICC (NCT03926338)

> Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03926338
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Sun Yat-sen University
- Conditions: Colorectal Cancer; Mismatch Repair-deficient (dMMR); Microsatellite Instability-high (MSI-H); Neoadjuvant Therapy
- Interventions: Neoadjuvant toripalimab plus celecoxib for 6 cycles; Neoadjuvant toripalimab monotherapy for 6 cycles; Neoadjuvant toripalimab plus celecoxib for 12 cycles; Neoadjuvant toripalimab monotherapy for 12 cycles; Toripalimab plus celecoxib as neoadjuvant or definitive therapy
- Enrollment: 270
- Primary outcome: Pathological complete response (pCR) rates (PICC-1 and PICC-2 cohorts)
- Primary outcome: Event-free survival (EFS) (PICC-3 cohort)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=picc-nct03926338